Lexicon Pharmaceuticals (LXRX) News Today $0.71 -0.02 (-2.20%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.73 +0.02 (+2.54%) As of 02/21/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Lexicon’s sotagliflozin shows cardiovascular efficacy in published studyFebruary 18, 2025 | markets.businessinsider.comPublished Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)February 18, 2025 | globenewswire.comH.C. Wainwright Keeps Their Buy Rating on Lexicon Pharmaceuticals (LXRX)February 14, 2025 | markets.businessinsider.comPromising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic PainJanuary 30, 2025 | markets.businessinsider.comLexicon Pharmaceuticals (NASDAQ:LXRX) Given Hold Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday.January 30, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday.January 30, 2025 | marketbeat.comLexicon Pharmaceuticals jumps amid takeover speculationJanuary 29, 2025 | seekingalpha.comLexicon Pharmaceuticals' (LXRX) "Hold" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday.January 29, 2025 | marketbeat.comLexicon Pharmaceuticals' (LXRX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday.January 29, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)January 27, 2025 | markets.businessinsider.comLexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic PainJanuary 21, 2025 | globenewswire.comHere’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | msn.comLexicon Pharmaceuticals, Inc.: Lexicon Appoints Scott Coiante as Chief Financial OfficerJanuary 2, 2025 | finanznachrichten.deLexicon Appoints Scott Coiante As CFO, SVPJanuary 2, 2025 | markets.businessinsider.comLexicon Pharmaceuticals Appoints New CFO Scott M. CoianteJanuary 2, 2025 | tipranks.comLexicon Pharmaceuticals Appoints Scott Coiante as Senior Vice President and Chief Financial OfficerJanuary 2, 2025 | quiverquant.comLexicon Appoints Scott Coiante as Chief Financial OfficerJanuary 2, 2025 | globenewswire.comPrivate equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%December 30, 2024 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)December 25, 2024 | markets.businessinsider.comAnalyst Expectations For Lexicon Pharmaceuticals's FutureDecember 23, 2024 | benzinga.comLexicon Pharmaceuticals' (LXRX) Hold Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday.December 23, 2024 | marketbeat.comLexicon Pharmaceuticals, Inc.: Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin)December 21, 2024 | finanznachrichten.deLexicon Receives Complete Response Letter from FDA for Diabetes, Kidney Disease TreatmentDecember 20, 2024 | marketwatch.comLexicon receives CRL for ZynquistaDecember 20, 2024 | markets.businessinsider.comFDA rejects Lexicon's Zynquista for diabetes, kidney diseaseDecember 20, 2024 | msn.comLexicon Pharmaceuticals Receives Complete Response Letter from FDA for Zynquista™ NDADecember 20, 2024 | quiverquant.comUS FDA declines to approve Lexicon Pharma's add-on diabetes drugDecember 20, 2024 | reuters.comLexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)December 20, 2024 | globenewswire.comPromising Investment Opportunity in Lexicon Pharmaceuticals’ LX9211 for Diabetic Peripheral Neuropathic PainDecember 13, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Reduces Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Point72 Asset Management L.P. lowered its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 70.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,230,050 shares of the biopharmaceutical compDecember 10, 2024 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Holdings Boosted by Fmr LLCFmr LLC lifted its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 28.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 49,867,042 shares of the biopharmaceutical company's stock after acquiring an additional 11,179,919 shDecember 6, 2024 | marketbeat.comBraidwell LP Has $1.26 Million Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Braidwell LP decreased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 90.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 801,584 shares of the biopharmaceutical company's stock after selling 7,493,November 29, 2024 | marketbeat.comLexicon announces completion of enrollment in Phase 2B PROGRESS studyNovember 26, 2024 | markets.businessinsider.comLexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and RestructuringNovember 26, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Completes Patient Enrollment for PROGRESS Study of LX9211, Exceeding Targets by 20%November 26, 2024 | quiverquant.comLexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)November 26, 2024 | globenewswire.comLexicon Pharmaceuticals to Participate in December Investor ConferencesNovember 25, 2024 | globenewswire.comLexicon Pharmaceuticals to cut 60% of workforceNovember 24, 2024 | investing.comLexicon Pharmaceuticals (LXRX) Receives a Hold from NeedhamNovember 23, 2024 | markets.businessinsider.comLexicon to eliminate commercial organization, focus on clinical developmentNovember 22, 2024 | markets.businessinsider.comLexicon Pharmaceuticals to lay off 60% of workforce after FDA setbackNovember 22, 2024 | msn.comNeedham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Friday.November 22, 2024 | marketbeat.comLexicon Pharmaceuticals Announces Strategic Restructuring to Focus on R&D and Cut Operating Costs by $100 MillionNovember 22, 2024 | quiverquant.comLexicon Pharmaceuticals to cut workforce by 60% to focus on drug developmentNovember 22, 2024 | reuters.comLexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDANovember 22, 2024 | globenewswire.comLexicon Pharmaceuticals Appoints Ivan Cheung to BoardNovember 20, 2024 | markets.businessinsider.comIvan H. Cheung Elected to Board of Directors of Lexicon Pharmaceuticals, Inc.November 20, 2024 | quiverquant.comLexicon Appoints Ivan H. Cheung to Board of DirectorsNovember 20, 2024 | globenewswire.comLexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market ActivityNovember 20, 2024 | gurufocus.comLexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past weekNovember 18, 2024 | finance.yahoo.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.000.60▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼24▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EBS News RIGL News CDXS News XOMA News IRWD News VSTM News VNDA News SGMO News ACHV News AGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXRX Stock Alerts